Stock Track | SINO BIOPHARM Soars 6.83% Intraday on $1.53 Billion Licensing Deal with Sanofi

Stock Track03-05

SINO BIOPHARM's stock surged 6.83% intraday on Thursday, marking a significant upward movement for the pharmaceutical company.

The sharp rise follows the announcement of an exclusive global licensing agreement with Sanofi for rovadicitinib, a novel oral JAK/ROCK inhibitor. Under the deal, SINO BIOPHARM's subsidiary granted Sanofi exclusive rights to develop and commercialize the drug, making the company eligible for up to $1.53 billion in payments including a $135 million upfront fee and milestone payments, plus tiered royalties on future sales.

This partnership represents a major validation of SINO BIOPHARM's research pipeline and provides substantial potential future revenue streams, driving investor optimism during the trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150164907?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 10:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150164907","market":"sg","top_or_hot":-1,"title":"Stock Track | SINO BIOPHARM Soars 6.83% Intraday on $1.53 Billion Licensing Deal with Sanofi","media":"Stock Track","content":"<p>SINO BIOPHARM's stock surged 6.83% intraday on Thursday, marking a significant upward movement for the pharmaceutical company.</p><p>The sharp rise follows the announcement of an exclusive global licensing agreement with Sanofi for rovadicitinib, a novel oral JAK/ROCK inhibitor. Under the deal, SINO BIOPHARM's subsidiary granted Sanofi exclusive rights to develop and commercialize the drug, making the company eligible for up to $1.53 billion in payments including a $135 million upfront fee and milestone payments, plus tiered royalties on future sales.</p><p>This partnership represents a major validation of SINO BIOPHARM's research pipeline and provides substantial potential future revenue streams, driving investor optimism during the trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SINO BIOPHARM Soars 6.83% Intraday on $1.53 Billion Licensing Deal with Sanofi</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SINO BIOPHARM Soars 6.83% Intraday on $1.53 Billion Licensing Deal with Sanofi\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-05 10:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SINO BIOPHARM's stock surged 6.83% intraday on Thursday, marking a significant upward movement for the pharmaceutical company.</p><p>The sharp rise follows the announcement of an exclusive global licensing agreement with Sanofi for rovadicitinib, a novel oral JAK/ROCK inhibitor. Under the deal, SINO BIOPHARM's subsidiary granted Sanofi exclusive rights to develop and commercialize the drug, making the company eligible for up to $1.53 billion in payments including a $135 million upfront fee and milestone payments, plus tiered royalties on future sales.</p><p>This partnership represents a major validation of SINO BIOPHARM's research pipeline and provides substantial potential future revenue streams, driving investor optimism during the trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1150164907","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150164907","pubTimestamp":1772678559,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"SINO BIOPHARM's stock surged 6.83% intraday on Thursday, marking a significant upward movement for the pharmaceutical company.The sharp rise follows the announcement of an exclusive global licensing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"个股追踪|中国生物制药盘中大涨6.83%与赛诺菲达成15.3亿美元授权协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"SINO BIOPHARM's stock surged 6.83% intraday on Thursday, marking a significant upward movement for the pharmaceutical company.The sharp rise follows the announcement of an exclusive global licensing agreement with Sanofi for rovadicitinib, a novel oral JAK/ROCK inhibitor. Under the deal, SINO BIOPHARM's subsidiary granted Sanofi exclusive rights to develop and commercialize the drug, making the company eligible for up to $1.53 billion in payments including a $135 million upfront fee and milestone payments, plus tiered royalties on future sales.This partnership represents a major validation of SINO BIOPHARM's research pipeline and provides substantial potential future revenue streams, driving investor optimism during the trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150164907","isCrawlerRequest":true}